In the heart of California’s Central Valley, where the sun beats down with the intensity of a thousand hair dryers and the air is thick enough to chew, is Ziveli Winery — a Croatian-inspired oasis in a sea of raisins and table grapes. It’s like someone took a slice of the

Out now in Nature Cancer. Our brand-new paper shows co-targeting of KRASG12C plus SOS1 as strategy for treating KRAS-G12C inhibitor-naïve and relapsed mutant tumors. Thanks to MD Anderson Cancer Center, Tim Heffernan and team and congrats to the Boehringer Ingelheim #KRAS team nature.com/articles/s4301…

On the music note! 🎶 🧬🔬💊 Molecular Cell NEJM 🔻 x.com/crozrx/status/…

The constantly evolving knowledge about the complexity of the cancer niche and the dynamic interactions between all its components has changed the way we think about tumors. The highly complex and heterogenous ecosystem of a tumour not only contains malignant cells, but also

🔸️ "Colorectal Cancer is not a single disease, but a complex collection of subtypes with unique genomic landscapes." soria 🔸️ "We should not call cancer in the singular, we should say oncological diseases." Mariano Barbacid 🔸️ udaibanerji calling it "an evil genius"!

ETAC-S, a framework for optimising tumour-agnostic 💊 drug development and for accelerating patient access to effective therapies. 🎯

6th Annual RAS-Targeted Drug Development Summit 🎯 🔸️ September 24-26, 2024 Boston MA 🔻 ras-drugdevelopment.com

RAS -ON inhibition overcomes clinical resistance to KRAS G12C -OFF covalent blockade. 🔻 doi.org/10.1038/s41467…

#GI24 Jun Gong Alfredo Addeo MD Oncology Brothers

🚨Pleased to share the pre-proof version of the editorial commentary just published ESMO - Eur. Oncology flagship journal Annals of Oncology 👉 Optimizing Tomorrow’s Drug Development with Project Optimus: Precision Dosing IS Precision Oncology 🎯💊💉#Oncology #DrugDevelopment

Excited to co-organize the virtual EACR Boehringer Ingelheim Conference: Drugging & Regulating the MAP Kinase Pathway! Submit an abstract or join us. Please RT and share with others. Details & registration: eacr.org/conference/boe…

Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown Primary #CUP 🔸️ Obtaining a molecular diagnosis along with molecular profiling may allow more patients with CUP or

Mechanisms of resistance to #KRAS G12C inhibitors in KRAS G12C-mutated non-small cell lung cancer 🫁 #NSCLC 🔻 doi.org/10.3389/fonc.2…

⚠️ Staging of patients with early pancreatic cancer is inaccurate as much as 80% of the time, according to a new study. 🔸️ In this study, investigators looked at data from more than 48,000 patients in the National Cancer Database. Based on preoperative imaging, all of the